CN105148263A - Porcine circovirus inactivated vaccine and porcine cytokine combined immune method - Google Patents
Porcine circovirus inactivated vaccine and porcine cytokine combined immune method Download PDFInfo
- Publication number
- CN105148263A CN105148263A CN201510642711.3A CN201510642711A CN105148263A CN 105148263 A CN105148263 A CN 105148263A CN 201510642711 A CN201510642711 A CN 201510642711A CN 105148263 A CN105148263 A CN 105148263A
- Authority
- CN
- China
- Prior art keywords
- inactivated vaccine
- porcine
- pcv2
- immunity
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides a porcine circovirus inactivated vaccine and porcine cytokine combined immune method. The porcine circovirus inactivated vaccine and porcine cytokine combined immune method is characterized in that porcine circovirus inactivated vaccine and porcine cytokine are simultaneously injected, wherein porcine cytokine is one of IL-4, a composition of IL-2 and IL-4, porcine gene engineering interferon and a porcine transfer factor. According to the porcine circovirus inactivated vaccine and porcine cytokine combined immune method, interleukin 2,4 and PCV2 inactivated vaccine are used together for immunity, so that the piglet cell immunity level can be remarkably improved; IL-4 and PCV2 inactivated vaccine are used in combination to remarkably reduce the sickness rate and the mortality of piglets, improve the average daily weight increment and feed conversion of the piglets and remarkably improve the economic benefits. Recombinant porcine interferon and PCV2 inactivated vaccine are used in combination to improve the survival rate of the piglets, reduce the sickness rate of the piglets and improve the antibody level after PCV2 vaccine immunity; the transfer factor and PCV2 inactivated vaccine are used in combination to shorten the immunity blanking period, improve the immunity effect and reduce the sickness rate.
Description
Technical field
The present invention relates to a kind of immunization method, particularly a kind of combined immunization method of pig circular ring virus inactivated vaccine and porcine cytokine.
Background technology
Porcine circovirus desease (PCVD) is the pig transmissible disease caused by porcine circovirus 2 type (PCV2), except initiation pmws (PMWS), also can cause the diseases such as the scorching nephrotic syndrome (PDNS) of sow breeding difficulty, Corii Sus domestica, newborn piglet congenital tremors (CT), Hypertrophic necrotizing pneumonia (PNP) and enteritis, be also that to cause the protopathy of porcine respiratory disease syndrome (PRDC) one of former simultaneously.This disease is the trend risen year by year at the positive rate of China, there is wide, each growth stage pig of Epidemic Scope and infect the features such as serious, mixed infection is outstanding, it is one of principal element in many cause of diseases multifactorial " innominate high fever syndrome " of China's happening and prevelence in recent years, become the number one killer that the current pig industry of restriction is stablized, developed, the development of serious threat China pig industry.The application of commercialization PCV inactivated vaccine brings positive meaning to the control of China PCVD, but porcine circovirus 2 type inactivated vaccine immune effect after scale pig farm uses is uncertain.How to improve and improve porcine circovirus type 2 vaccines immune effect oneself become current immune Research field and the prevention important topic of veterinary practice and study hotspot.
Summary of the invention
The present invention is directed to above shortcoming, a kind of pig circular ring virus inactivated vaccine and porcine cytokine combined immunization method are provided, to reach the object of the immune effect improving and improve porcine circovirus type 2 vaccines.
For achieving the above object, the present invention takes following technical proposals to realize:
A kind of pig circular ring virus inactivated vaccine and porcine cytokine combined immunization method, described combined immunization method is inject pig circular ring virus inactivated vaccine and porcine cytokine simultaneously, and wherein porcine cytokine is IL-4, IL-2,4 couplings, the one in pig genetic engineering interferon and Transfer Factor-porcine.
Further, described porcine cytokine is IL-4, IL-2,4 couplings, and the one in Transfer Factor-porcine.
Further, described porcine cytokine is Transfer Factor-porcine.
Further, piglets 14 age in days and 28 ages in days inject PCV2 inactivated vaccine 1mL and IL-2 respectively, 40.1mL.
Further, piglets 13-15 age in days, injects the IL-4 of PCV2 inactivated vaccine 1 part and 250,000 IU respectively on the same day and latter 14 days.
Further, piglets 14 age in days and 28 ages in days, musculi colli injection PCV2 inactivated vaccine 1ml, another side musculi colli injection pig genetic engineering interferon.
Further, piglets 14 age in days and 28 ages in days, through musculi colli injecting immune, distinguish intramuscular injection PCV2 inactivated vaccine 1mL and pig transfer factor 0.1mL.
In a word, beneficial effect of the present invention is:
Combined immunization method interleukin II of the present invention, 4 can significantly improve piglet cellular immune level with PCV2 inactivated vaccine combined immunization; IL-4 and PCV2 inactivated vaccine conbined usage, significantly can reduce the M & M of piglet, improves piglet average daily gain and the price of deed, significantly improves economic benefit.Recombinant Swine interferon and PCV2 inactivated vaccine conbined usage can improve the survival rate of piglet, reduce the sickness rate of piglet, improve the antibody horizontal after PCV2 vaccine immunity; Transfer factor and PCV2 inactivated vaccine combined immunization can shorten the Blank immunization phase, improve immune effect, reduce sickness rate.
Detailed description of the invention
Describe the present invention below in conjunction with specific embodiment.
Embodiment 1
IL-2,4 test with pig PCV2 inactivated vaccine use in conjunction
Test method:
Similar genetic background, 14 ages in days " Du × long × large " three way cross sodium selenite 60 are selected in test, are divided into 2 groups at random, often organize 3 repetitions, each repetition 10 pigs.Conventional feeding and management, free choice feeding and freely drinking water.Test group is in 14 ages in days and 28 ages in days injection PCV2 inactivated vaccine 1mL+IL-2,40.1mL, and matched group is in 14 ages in days and 28 ages in days injection PCV2 inactivated vaccine 1mL.
Test the 21st, 35,49d gathers blood 2 parts respectively at each group of random selecting 4 piglets (male and female half and half) vena cava anterior, 1 part of 2mL injects aseptic penicillin bottle, adds heparin sodium anticoagulant, for blood lymphocytes conversion test.1 part with ethylenediamine tetraacetic acid,dipotassium salt (EDTA-K2) anticoagulant tube blood sampling 1mL, for differential blood count.
In test the 28th, 42d early morning, each group random selecting 4 piglets (male and female half and half), butchers after weighing, before butchering under free conditions of water drinking fasting 24h.Jugular vein blood-letting, cuts open the chest to take inguinal lymph nodes, submandibular lymph nodes, liver, spleen and thymus, and rejects connective tissue above, for detecting each Immune Organs Index.
Experimental result:
IL-2,4 impacts on piglet immunological shoot formation
Table 1IL-2,4 impacts on piglet immunological shoot formation
Result of study is shown in and shows, during test 28d (42 age in days), test group piglet inguinal lymph nodes index, submandibular lymph nodes number, liver index, index and spleen index and thymus index respectively higher than matched group by 9.64%, 15.04%, 7.23%, 22.79% and 19.23%, wherein index and spleen index and thymus index significant difference (P < 0.05), other several Immune Organs Index differences are not significantly (P > 0.05); During test 42d (56 age in days), test group piglet inguinal lymph nodes index, submandibular lymph nodes index, liver index, index and spleen index and thymus index respectively higher than matched group by 18.58%, 20.59%, 2.68%, 35.04% and 18.96%, wherein liver index difference is not significantly (P > 0.05), other each Immune Organs Index differences all significantly (P < 0.05), IL-2 is described, 4 can improve the immunity of piglet with PCV2 inactivated vaccine combined immunization.When matched group and test group piglet 56 age in days, each Immune Organs Index is all high than 42 ages in days, illustrates that the immunity of piglet 42d is stronger than 28d after the immunity of PCV2 inactivated vaccine.
2.IL-2,4 impacts on piglet lymhocyte transformation rate
Table 2IL-2,4 impacts on piglet lymhocyte transformation rate
Result of the test shows, and test group different days lymhocyte transformation rate is all significantly higher than matched group (P < 0.05).Show IL-2,4 can strengthen Cell-mediated Immunity.
3.IL-2,4 impacts on the differential counting of piglet peripheral blood cells
Table 3 interleukin is on the impact of piglet peripheral blood cells differential counting
Result of the test shows, IL-2,4 are used alone the immunity of PCV2 inactivated vaccine with PCV2 inactivated vaccine combined immunization ratio, during 35d and 49d, peripheral white blood cell amount and lymphocyte quantity significantly increase (P < 0.05), erythrocyte and neutrophilic granulocyte quantity have the trend of rising, but do not make significant difference (P > 0.05).
Interleukin II, 4 can significantly improve piglet cellular immune level with PCV2 inactivated vaccine combined immunization: IL-2, and 4 are all used alone PCV2 inactivated vaccine higher than being significantly higher than with PCV2 combined immunization piglet inguinal lymph nodes index, submandibular lymph nodes index, liver index, index and spleen index and thymus index; IL-2,4 are all significantly higher than are used alone PCV2 inactivated vaccine with PCV2 combined immunization lymhocyte transformation rates; IL-2,4 are used alone PCV2 inactivated vaccine with PCV2 combined immunization peripheral white blood cell amount and lymphocyte quantity ratio significantly increases.IL-2 is described, 4 effectively can promote the cellular immune function of piglet with PCV2 inactivated vaccine combined immunization, improve the immunity of piglet.
Embodiment 2
IL-4 and pig PCV2 inactivated vaccine use in conjunction are tested
Test method:
Selection 13-15 age in days, the DLY hybridization piglet 120 that body weight is close, genetic background is identical, be divided into 3 groups at random, often establish 4 repetitions in group, each repetition 10.Rear 14d injected PCV2 inactivated vaccine 1 part+pig interleukin-4 (IL-4) 250,000 IU, PCV2 inactivated vaccine 1 part and normal saline 1mL respectively with test same day on-test to test each group.
After above-mentioned immunity test terminates, then 13-15 age in days piglet 633 is selected to carry out jumpbogroup test.Test pig is divided into 2 groups at random, one group of injection PCV2 inactivated vaccine, 1 part+IL-425 ten thousand IU, another group only injection PCV2 inactivated vaccine 1 part does not inject interleukin, and interval 14d repeats immunity once, records 91 age in days body weight, food consumption, sickness rate and survival rate.
Experimental result:
The impact of table 4IL-4+PCV2 inactivated vaccine immunity on weaned piglets
Result of the test shows, on-test (14 age in days), terminated (56 age in days) to the first stage, it is 378.6g that IL-4 combines the average daily gain of PCV2 inactivated vaccine immunity piglet, respectively than using separately the immunity of PCV2 inactivated vaccine and improving 11.98% and 25.20%, significant difference (P < 0.05) without vaccine.On-test (14 age in days), terminates (91 age in days) to second stage, it is 529.9g that IL-4 combines the average daily gain of PCV2 inactivated vaccine immunity piglet, than improving 6.26% with the immunity of PCV2 inactivated vaccine separately, difference is not significantly (P > 0.05), 17.60% is improved, significant difference (P < 0.05) than without vaccine.Along with the increase of piglet age in days, two kinds of immunization methods are reducing the impact of piglet average daily gain.
During 91 age in days, it is 21.49% that IL-4 combines PCV2 inactivated vaccine immunity piglet sickness rate, than declining 26.18% with the immunity of PCV2 inactivated vaccine separately, significant difference (P < 0.05), decline 52.24% than without vaccine, difference extremely significantly (P < 0.01).It is 5% that IL-4 combines PCV2 inactivated vaccine immunity piglets phase mortality rate, and respectively than using separately the immunity of PCV2 inactivated vaccine and declining 33.33% and 60% without vaccine, difference extremely significantly (P < 0.01).
It is 2.06 that whole experimental period IL-4 combines PCV2 inactivated vaccine immunity baby pig feedstuff anharmonic ratio, than reducing by 6.79% with the immunity of PCV2 inactivated vaccine separately, difference is not significantly (P > 0.05), reduce by 24.82% than without vaccine, difference extremely significantly (P < 0.01).
By in table, the computational methods of gross profit are described, experimental period IL-4 combines PCV2 inactivated vaccine immunity every piglet gross profit than separately with immune many 38.9 yuan of PCV2 inactivated vaccine, earns 132.90 yuan than not immune group more.Coordinate pig interleukin to use when piglet pig circular ring virus vaccine immunity is described, more economic benefit can be brought to pig farm.
Table 5PCV vaccine+IL-4 jumpbogroup immunity test result
PCV vaccine associating IL-4 jumpbogroup immunity test result shows, it is 94.22% that IL-4 combines PCV2 inactivated vaccine immunity piglet survival ratio, than improving 2.95 percentage points with the immunity of PCV2 inactivated vaccine separately, average daily gain improves 36g, feed-weight ratio reduces by 0.12, basically identical with groupuscule result of the test.
IL-4 combines the average daily gain of PCV2 inactivated vaccine immunity piglet than improving 6.26%-11.98% with the immunity of PCV2 inactivated vaccine separately, and baby pig feedstuff anharmonic ratio reduces by 6.79%, and piglets phase mortality rate declines 33.33%, and every piglet gross profit increases by 38.9 yuan.Coordinate pig interleukin to use when piglet pig circular ring virus vaccine immunity is described, more economic benefit can be brought to pig farm.Interleukin (IL) has more research as vaccine immunity adjuvant recent domestic, but does not have the research of IL-4 and PCV2 inactivated vaccine conbined usage.IL-4 is verified in this research can become the new and effective immunostimulant of pig PCV2 vaccine, promotes the immune protection that PCV2 infects.IL-4 and PCV2 inactivated vaccine conbined usage, significantly can reduce the M & M of piglet, improves piglet average daily gain and the price of deed, significantly improves economic benefit.
Embodiment 3
Pig genetic engineering interferon and PCV2 inactivated vaccine use in conjunction are tested
Test method:
14 age in days piglets 60 are divided into A, B, C, D tetra-groups at random, often organize 15.Processed group and matched group all inject PCV2 inactivated vaccine 1ml/ head in 14 ages in days and 28 age in days musculi collis, but processed group is simultaneously in another side musculi colli injection pig genetic engineering interferon, A group dosage is 500,000 active units, B group 250,000 active unit, C group 12.5 ten thousand active unit, D group is blank, does not inject pig genetic engineering interferon.
ELISA measures each group of antibody respectively at 14d, 21d, 28d and 35d vena cava anterior blood sampling after first immunity, carries out PCV2 antibody test.PCV2 antibody test in blood serum sample operates by the description of century Yuan Heng company porcine circovirus 2 type antibody enzyme-linked immunologic diagnosis kit, and its criterion is: P >=0.6, during N≤0.15, and S/P >=0.25, test sample is PCV2 antibody positive; S/P ﹤ 0.25, test sample is PCV2 negative antibody.
Neutralizing antibody detects each group respectively at 14d, 21d, 28d and 35d vena cava anterior blood sampling after first immunity, separation of serum according to a conventional method, by serum 56 DEG C of deactivation 30min, 2 times of serial dilutions (21-27) are done with the MEM culture fluid containing 2% Ox blood serum, each dilution factor is got 500 μ L serum and is mixed with the PCV-2SH strain virus liquid of 500 μ L200TCID50,37 DEG C of effect 1h; Add in 96 well culture plates covering with monolayer PK-15 cell, every hole adds 100 μ L, and each dilution factor adds 4 multiple holes; Be placed in 37 DEG C, 50mL/LCO2 incubator cultivates 72h, wash 3 times with PBS liquid, acetone fixes 15-30min; Wash 3 times with PBS liquid again, close 2h with containing 10%BSA, rinse 3 times, each 5min; Add primary antibodie (the anti-PCV-2 serum of rabbit), 37 DEG C of effect 2h, rinse 3 times; Add two anti-(goat anti-rabbit iggs of fluorescein isothiocyanate labelling), room temperature lucifuge effect 1h, rinses 3 times; Blot, in fluorescence microscopy Microscopic observation.Be judged to the positive with typical yellow-green fluorescence visible in cell, calculate TCID50 value by Reed-Muench method.
Random selecting 2 piglets (male and female half and half) are respectively organized, per os, rhinovaccination PCV2-SH strain 2mL, musculi colli injection inoculation 3mL during counteracting toxic substances piglet blood-serum P CV-2 antibody test 49 age in days.14d, 21d, 28d and 35d piglet blood-serum P CV-2 antibody horizontal after each group of counteracting toxic substances is measured by 1.4.1 method.
Experimental result:
Table 6 piglet PCV2ELISA antibody (S/P value)
Table 7 piglet PCV2 neutralizing antibody (TCID
50value)
Piglet PCV2ELISA antibody (S/P value) after table 8 counteracting toxic substances
Result of study shows, 14d after head exempts from, blood-serum P CV2ELISA antibody and SN antibody start to rise, and head exempts from rear 28d and reaches peak value, starts afterwards to decline.Wherein middle dosage (250,000 active unit) interferon group ELISA antibody and SN antibody the highest, be significantly higher than low dose group and high dose group, pole is significantly higher than matched group; Low dose group is a little more than high dose group and matched group, but between three groups, difference is not remarkable.It can thus be appreciated that when PCV2 immunity, associating interferon can play synergism, strengthens immune effect, but has certain relation with the dosage of interferon.Protest test shows; test group and matched group all can induce pig to produce specific immune response; namely PCV2ELISA antibody raise after experiencing of short duration decline, PCV-2 inactivated vaccine is described or all can plays a good protection to piglet with interferon combined immunization.
The Recombinant Swine interferon of doses and PCV2 inactivated vaccine conbined usage can improve the survival rate of piglet, reduce the sickness rate of piglet; improve the antibody horizontal after PCV2 vaccine immunity: recombinant porcine alpha interferon has stronger immunoregulation effect to proteantigen under appropriate condition; while virus replication, can promote that again virus-specific protects the generation of immunity.Result of the test shows, interferon and the PCV2 inactivated vaccine conbined usage of 250,000 active units can play optimum antibody level, for Clinical practice interferon provides reference frame.
Embodiment 4
Transfer factor and PCV2 inactivated vaccine use in conjunction are tested
Test method:
Be divided into 3 groups at random by detecting 60 14 age in days health Du × (long × large) piglet that PCV2 antibody horizontal is consistent, body weight is close through ELISA, often organize 2 repetitions, each repetition 10.Press pig farm routine healthcare, sterilization and immunity for each group, special messenger is responsible for feeding and management, and environmental condition is consistent.Examination pig free choice feeding, freely drinks water.Test piglet is respectively at 14 ages in days and 28 ages in days through musculi colli injecting immune, and the intramuscular injection of A group PCV2 inactivated vaccine 1mL/ head, B group PCV2 inactivated vaccine 1mL/ head and pig transfer factor 0.1mL/ head distinguish intramuscular injection, the intramuscular injection of C group normal saline 1mL/ head.In first time immunity after the 7th, 14,21,28,35,42,49,56,63d respectively through vena cava anterior to test piglet blood sampling, numbering, the centrifugal 10min of 3000rpm, separation of serum ,-20 DEG C save backup.
In serum, PCV2 specific antibody level detects and adopts PCV2-ELISA antibody assay kit to detect PCV2 specific antibody level (operating by test kit operation instructions) in each test group serum sample, and draws the dynamic its growth of antibody horizontal.
Serum IgG, IgA and IgM detect serum immune globulin (IgG, IgM, IgA) assay and adopt immune turbidimetry, measure on RXDAYTONA automatic clinical chemistry analyzer (operating by test kit operation instructions) with Immunoglobulin reagents box, and draw the dynamic its growth of various immunoglobulin.
The mensuration of piglet growth performance is respectively at on-test and off-test that morning 8:00 precise piglet weight on an empty stomach, and every day often organized test piglet feed intake in record.Calculate average daily gain (ADG) and the feed-weight ratio in each stage (F/G) in each stage.If occur, piglet is dead, and when it is dead, body weight is counted and tested last weight.Every day viewing test pig incidence, occur that depressed, the inappetence of spirit, constipation or diarrhoea, cough, asthma or dyspnea, body temperature rising etc. are all designated as morbidity.
Experimental result:
1. transfer factor and PCV2 inactivated vaccine combined immunization are on the impact of piglet growth performance
Table 9 piglet growth performance (kg)
Result of the test shows, transfer factor and the piglets phase average daily gain of PCV2 inactivated vaccine combined immunization are 0.487kg, immune average daily gain 0.464kg more independent than PCV2 inactivated vaccine improves 4.96%, difference is not significantly (P>0.05), than not immune group average daily gain 0.438kg raising 11.19%, significant difference (P<0.05), the independent immune group ratio of PCV2 inactivated vaccine not immune group average daily gain improves 5.94%, significant difference (P<0.05).Transfer factor and PCV2 inactivated vaccine combined immunization piglets phase feed-weight ratio 1.723, than the immunity reduction by 5.59% separately of PCV2 inactivated vaccine, difference is not significantly (P>0.05), than not immune group reduction by 19.22%, difference extremely significantly (P<0.01); The independent immune group ratio of PCV2 inactivated vaccine not immune group piglets phase feed-weight ratio reduces by 14.44%, significant difference (P<0.05).Result of the test shows, injection porcine circovirus vaccine can significantly improve piglet daily gain, and transfer factor and PCV2 inactivated vaccine combined immunization can improve piglet average daily gain more significantly than the independent immunity of PCV2 inactivated vaccine.
2. transfer factor and PCV2 inactivated vaccine combined immunization are on the impact of piglet M & M
Table 10 piglet M & M
Experimental result shows, transfer factor and PCV2 inactivated vaccine combined immunization group reduce by 28.85% than the independent immune group sickness rate of PCV2 inactivated vaccine, significant difference (P<0.05), than not immune group sickness rate reduction by 58.43%, difference extremely significantly (P<0.01), the independent immune group of PCV2 inactivated vaccine is than not immune group sickness rate reduction by 41.57%, and difference extremely significantly (P<0.01).Illustrate that injection porcine circovirus vaccine can extremely significantly reduce piglet M & M, transfer factor and PCV2 inactivated vaccine combined immunization piglet sickness rate significantly immune separately lower than PCV2 inactivated vaccine.
Experimental result shows, the independent immune group of PCV2 inactivated vaccine is exempted from rear antibody horizontal in head and started to decline, and drop to minimum point to 14d, after 14d, antibody horizontal starts quick rising, slowly rises to 35d antibody horizontal, and 56d starts after reaching peak value slowly to decline.Transfer factor and PCV2 inactivated vaccine combined immunization group are exempted from rear antibody in head and are started to decline, but start to rise to 7d antibody, rise until off-test afterwards always, and head exempt from after 7d start whole experimental period antibody horizontal all higher than the independent immune group of PCV2 inactivated vaccine, wherein 49d antibody horizontal improves 17.24%, significant difference (P<0.05).Illustrate that transfer factor can be worked in coordination with vaccine and effectively be induced body to produce specific humoral immunoresponse(HI), produce antibody fast, shorten the Blank immunization phase, improve immune effect.And blank group PCV2 antibody horizontal is in downward trend all the time, to test, 42d (56 age in days) antibody horizontal starts to rise, be maintained to off-test (after test 63d), possible piglet is subject to the infection of wild poison in about 56 ages in days.
Piglet is before vaccinate, and in each group serum, anti-PCV2 IgG antibody level is all higher, and the antibody sources now in piglet body is in breast milk.IgG level starts to decline after vaccination, and independent immune group IgG drops to minimum in 14d, starts afterwards to rise gradually until 56d, then has downward trend.Combined immunization group IgG level starts to decline after immunity, but 7d just starts to rise, and starts quick rising to 21d, then maintains always and slowly rises until off-test.Whole experimental period, combined immunization group IgG level is all the time higher than independent immune group, wherein 28d, 35d and 42d antibody horizontal improves 50.06%, 47.72% and 30.58% respectively, difference extremely significantly (P<0.01), 14d, 21d and 49d antibody horizontal improves 27.78%, 25.98% and 24.23% respectively, significant difference (P<0.05).Immune group is not along with the increase of piglet age in days, and IgG level declines gradually, starts to rise fast to 56 ages in days (after on-test 42d).
Experimental result shows, in two test group serum, IgA, IgM concentration all starts to decline after vaccinate, drops to minimum during 7d, starts afterwards to rise, and is stabilized in than antibody horizontal slightly high before immunity always.In combined immunization group serum, the independent immune group of IgA concentration ratio increases, but difference is not significantly (P>0.05) (table 5).Immune group IgA, IgM concentration are not in reduced levels always, immunity after two weeks beginning extremely remarkable lower than immune group (P<0.01) until off-test.Can significantly improve IgA, IgM concentration in serum in pole after piglet immunological PCV-2 inactivated vaccine is described, and transfer factor increases with PCV-2 inactivated vaccine combined immunization immune piglet serum IgA more independent than PCV-2 inactivated vaccine, IgM concentration.
Transfer factor can be worked in coordination with vaccine and effectively be induced body to produce specific humoral immunoresponse(HI), produces antibody fast, shortens the Blank immunization phase, improves antibody horizontal.Transfer factor and PCV2 inactivated vaccine combined immunization than the independent immunity of PCV2 inactivated vaccine can significantly or pole significantly improve serum IgG, IgA and IgM concentration, significantly improve piglet average daily gain, significantly reduce piglet sickness rate.
Although the present invention with preferred embodiment openly as above; but it is not for limiting the present invention; any those skilled in the art without departing from the spirit and scope of the present invention; the Method and Technology content of above-mentioned announcement can be utilized to make possible variation and amendment to technical solution of the present invention; therefore; every content not departing from technical solution of the present invention; according to technical spirit of the present invention to any simple modification made for any of the above embodiments, equivalent variations and modification, all belong to the protection domain of technical solution of the present invention.
Claims (7)
1. a pig circular ring virus inactivated vaccine and porcine cytokine combined immunization method, it is characterized in that, described combined immunization method is inject pig circular ring virus inactivated vaccine and porcine cytokine simultaneously, wherein porcine cytokine is IL-4, IL-2,4 couplings, the one in pig genetic engineering interferon and Transfer Factor-porcine.
2. combined immunization method according to claim 1, is characterized in that, described porcine cytokine is IL-4, IL-2,4 couplings, and the one in Transfer Factor-porcine.
3. combined immunization method according to claim 2, is characterized in that, described porcine cytokine is Transfer Factor-porcine.
4. combined immunization method according to claim 1, is characterized in that, piglets 14 age in days and 28 ages in days inject pig circular ring virus inactivated vaccine inactivated vaccine 1mL and IL-2 respectively, 40.1mL.
5. combined immunization method according to claim 1, is characterized in that, piglets 13-15 age in days, injects the IL-4 of pig circular ring virus inactivated vaccine inactivated vaccine 1 part and 250,000 IU respectively on the same day and latter 14 days.
6. combined immunization method according to claim 1, is characterized in that, piglets 14 age in days and 28 ages in days, musculi colli injection pig circular ring virus inactivated vaccine inactivated vaccine 1ml, another side musculi colli injection pig genetic engineering interferon.
7. combined immunization method according to claim 1, is characterized in that, piglets 14 age in days and 28 ages in days, through musculi colli injecting immune, distinguish intramuscular injection pig circular ring virus inactivated vaccine inactivated vaccine 1mL and pig transfer factor 0.1mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510642711.3A CN105148263A (en) | 2015-09-30 | 2015-09-30 | Porcine circovirus inactivated vaccine and porcine cytokine combined immune method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510642711.3A CN105148263A (en) | 2015-09-30 | 2015-09-30 | Porcine circovirus inactivated vaccine and porcine cytokine combined immune method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105148263A true CN105148263A (en) | 2015-12-16 |
Family
ID=54789522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510642711.3A Pending CN105148263A (en) | 2015-09-30 | 2015-09-30 | Porcine circovirus inactivated vaccine and porcine cytokine combined immune method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105148263A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693854A (en) * | 2016-04-01 | 2016-06-22 | 重庆三杰众鑫生物工程有限公司 | Preparation method of refined yolk antibody against duck tembusu virus |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101240264A (en) * | 2008-03-21 | 2008-08-13 | 南京农业大学 | Porcine circovirus 2 type inactivated vaccine |
| CN103623402A (en) * | 2013-11-27 | 2014-03-12 | 扬州优邦生物制药有限公司 | Preparation method of porcine circovirus type 2 inactivated vaccine |
| CN104771754A (en) * | 2015-04-02 | 2015-07-15 | 武汉科前生物股份有限公司 | Water-based adjuvant of porcine circovirus type 2 inactivated vaccine and application thereof |
-
2015
- 2015-09-30 CN CN201510642711.3A patent/CN105148263A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101240264A (en) * | 2008-03-21 | 2008-08-13 | 南京农业大学 | Porcine circovirus 2 type inactivated vaccine |
| CN103623402A (en) * | 2013-11-27 | 2014-03-12 | 扬州优邦生物制药有限公司 | Preparation method of porcine circovirus type 2 inactivated vaccine |
| CN104771754A (en) * | 2015-04-02 | 2015-07-15 | 武汉科前生物股份有限公司 | Water-based adjuvant of porcine circovirus type 2 inactivated vaccine and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 章红兵: "IL-4 与猪PCV2灭活疫苗联合应用效果研究", 《猪病防控》 * |
| 章红兵: "猪基因工程干扰素对PCV2 灭活疫苗抗体水平的影响", 《金华职业技术学院学报》 * |
| 章红兵: "猪白细胞介素-2，4 作为猪圆环病毒灭活疫苗免疫增强剂", 《中国预防兽医学报》 * |
| 章红兵: "转移因子对PCV2 灭活疫苗免疫效果的影响", 《中国预防兽医学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693854A (en) * | 2016-04-01 | 2016-06-22 | 重庆三杰众鑫生物工程有限公司 | Preparation method of refined yolk antibody against duck tembusu virus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saad et al. | Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases | |
| CN101871941A (en) | Porcine circovirus-II vaccine potency test method | |
| CN102258777B (en) | Method for preparing inactivated vaccine and combined vaccine by breeding infectious bursal disease virus (IBDV) by chicken embryo source cell line | |
| CN103263666A (en) | Duplex inactivated vaccine of porcine circovirus type 2 and porcine mycoplasma hyopneumoniae and preparation method of duplex inactivated vaccine | |
| Vaziry et al. | Chicken infectious anaemia vaccinal strain persists in the spleen and thymus of young chicks and induces thymic lymphoid cell disorders | |
| CN106497890A (en) | A kind of 1 plant of porcine pseudorabies virus variant XF and preparation method and application | |
| CN103436499A (en) | Porcine circovirus-like particle, and vaccine and preparation method thereof | |
| CN105606804A (en) | Porcine circovirus inactivated vaccine efficacy testing method | |
| Ingrao et al. | Characterization of two recombinant HVT-IBD vaccines by VP2 insert detection and cell-mediated immunity after vaccination of specific pathogen-free chickens | |
| CN102221618A (en) | Method for establishing hog cholera lapinized virus labeled vaccine strain and preparing vaccine | |
| Krametter‐Frötscher et al. | Serological survey for antibodies against pestiviruses in sheep in Austria | |
| CN101184500A (en) | Coccidial vaccine and methods of making and using same | |
| CN105148263A (en) | Porcine circovirus inactivated vaccine and porcine cytokine combined immune method | |
| CN103923885B (en) | Infections chicken cloacal bursa virus Vero cell adapted strain and application thereof | |
| CN108421037A (en) | A kind of porcine pseudorabies/porcine parvovirus bivalent inactivated vaccine and its culture preparation method that suspends | |
| Yang et al. | The synergy of chicken Anemia virus and gyrovirus homsa 1 in chickens | |
| CN105200015B (en) | A kind of porcine pseudorabies strain | |
| CN104288760A (en) | Vaccine composition, and preparation method and application thereof | |
| CN104771754A (en) | Water-based adjuvant of porcine circovirus type 2 inactivated vaccine and application thereof | |
| CN103864931A (en) | Preparation and freeze-dried storage method of pseudorabies standard positive serum | |
| CN104474542A (en) | Preparation method of bi-combined inactivated vaccine | |
| CN104857511B (en) | Thinner for vaccine containing panaxoside | |
| CN102719407B (en) | Porcine parvovirus BQ-C strain and application of porcine parvovirus BQ-C strain in preparation of inactivated porcine parvovirus vaccine | |
| CN105920595A (en) | Porcine circovirus type 2 inactivated vaccine and preparation method thereof | |
| CN1477192A (en) | Recombinant pseudo-rabies virus expressing swine parvovirus VP2 gene and vacine and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151216 |
|
| RJ01 | Rejection of invention patent application after publication |